The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

By Ludwig Burger FRANKFURT, Jan 29 (Reuters) - Roche's adjusted operating income rose by a lower-than-expected 5% in 2025 as ...

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting Tuesday that the drug led ...

While AI has yet to crack the most complex problem in drug development, discovering breakthrough medicines, pharmaceutical ...

AI in drug discovery offers key market opportunities by enhancing drug development efficiency, reducing costs, and improving success rates. It supports personalized medicine, facilitating custom ...